RPG Life Sciences Share Price Crashes Over 10% After Q2 FY27 Results

Written by: Team Angel OneUpdated on: 30 Oct 2026, 5:18 pm IST

RPG Life Sciences recorded a 16.5% increase in Q2 FY27 revenue, taking its quarterly revenue to ₹211.6 crore from ₹181.7 crore a year earlier.

RPG Life Sciences reported revenue from operations of ₹211.6 crore for the quarter ended September 30, 2026, against ₹181.7 crore in the year-ago period, an increase of 16.5%. The company announced its results on October 29, 2026.

Adjusted EBITDA rose 15% to ₹50.1 crore from ₹43.6 crore. The adjusted EBITDA margin was 23.7%, compared with 24% a year earlier. Gross margin increased by 260 basis points.

Adjusted profit before tax grew 11.3% to ₹42.5 crore from ₹38.2 crore. Adjusted profit after tax was ₹32.3 crore, against ₹28.5 crore in Q2 FY26, an increase of 13.4%. These figures exclude ₹5.5 crore in one-off API acquisition and restructuring costs. Reported EBITDA, after these costs, was ₹44.7 crore.

Domestic and International Formulations

Domestic formulations revenue increased 11.6% to ₹145.7 crore from ₹130.6 crore. The company attributed the increase to volume growth and sales across specialty therapies.

It moved from 62nd position in the Indian Pharmaceutical Market in March 2025 to 50th in September 2026, becoming the fourth-fastest-growing company among the top 50 players. Naprosyn crossed ₹100 crore in secondary sales.

International formulations revenue rose 6.4% to ₹36.7 crore from ₹34.5 crore. The company cited sales growth across key products and markets.

Its priorities for the segment include new market registrations, contract development and manufacturing (CDMO) opportunities and business development.

API Business

API revenue was ₹28 crore, up 89.2% from ₹14.8 crore in Q2 FY26. During the quarter, RPG Life Sciences transferred its API business to RPG Active Pharma, brought InvAscent in as an investor and completed the acquisitions of Actis Generics and Raghava Life Sciences.

The expanded network has five times the manufacturing capacity and four times the reactors.

Half-Year Performance

For H1 FY27, revenue increased 16.2% to ₹407.3 crore. Adjusted EBITDA rose 16.1% to ₹97.9 crore, while adjusted PAT increased 14.8% to ₹62.9 crore.

As of October 30, 2026, 11:18 am, RPG Life Sciences share price was trading at ₹2,698.90, a 10.15% decrease from the previous closing price.

Conclusion

The company recorded higher revenue and profit in Q2 FY27, with all three business segments reporting year-on-year growth. H1 FY27 revenue increased to ₹407.3 crore.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Published on: Oct 30, 2026, 11:48 AM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.

Know More